Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.19−1.16 (-10.22%)
Close on Nov 12, 2026Market cap $655.77MP/E –Yield –
Cullinan Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Cullinan Therapeutics's total assets was $322.56M at Sep 30, 2026. For fiscal 2025 it was $448.37M, down 27.9% from the year before. The highest annual figure on record is $621.82M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $448.37M | -27.9% |
| FY2024 | Dec 31, 2024 | $621.82M | +28.4% |
| FY2023 | Dec 31, 2023 | $484.18M | -13.7% |
| FY2022 | Dec 31, 2022 | $561.12M | +28.3% |
| FY2021 | Dec 31, 2021 | $437.19M | +103.6% |
| FY2020 | Dec 31, 2020 | $214.71M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $322.56M | -33.4% |
| Q2 FY2026 | Jun 30, 2026 | $363.79M | -30.1% |
| Q1 FY2026 | Mar 31, 2026 | $402.98M | -30.5% |
| Q4 FY2025 | Dec 31, 2025 | $448.37M | -27.9% |
| Q3 FY2025 | Sep 30, 2025 | $484.13M | -25.9% |
| Q2 FY2025 | Jun 30, 2025 | $520.33M | -23.6% |
| Q1 FY2025 | Mar 31, 2025 | $579.68M | +29.0% |
| Q4 FY2024 | Dec 31, 2024 | $621.82M | +28.4% |
| Q3 FY2024 | Sep 30, 2024 | $653.25M | +32.0% |
| Q2 FY2024 | Jun 30, 2024 | $681.22M | +30.5% |
| Q1 FY2024 | Mar 31, 2024 | $449.43M | -12.7% |
| Q4 FY2023 | Dec 31, 2023 | $484.18M | -13.7% |
| Q3 FY2023 | Sep 30, 2023 | $494.71M | -19.9% |
| Q2 FY2023 | Jun 30, 2023 | $521.98M | -21.8% |
| Q1 FY2023 | Mar 31, 2023 | $514.99M | +17.7% |
| Q4 FY2022 | Dec 31, 2022 | $561.12M | +28.3% |
| Q3 FY2022 | Sep 30, 2022 | $617.24M | +36.1% |
| Q2 FY2022 | Jun 30, 2022 | $667.25M | +43.7% |
| Q1 FY2022 | Mar 31, 2022 | $437.46M | -8.8% |
| Q4 FY2021 | Dec 31, 2021 | $437.19M | +103.6% |
| Q3 FY2021 | Sep 30, 2021 | $453.40M | – |
| Q2 FY2021 | Jun 30, 2021 | $464.35M | – |
| Q1 FY2021 | Mar 31, 2021 | $479.67M | – |
| Q4 FY2020 | Dec 31, 2020 | $214.71M | – |
See a number that looks wrong?